Markets

SL Science Presents Benefits Of Gamma Delta T Cells In Eliminating Glioblastoma In Preclinical Studies At The 2026 World Congress Of Basic And Clinical Pharmacology

Jul 17, 2026 · 08:08 AM ET· updated 10h ago

SL Science Holding Limited (NASDAQ:SLBT) ("SL Science" or the "Company"), a biotechnology company developing next-generation immune cell therapies, today announced its successful exhibition and

Why It Matters

SL Science showed that a special type of immune cell might help fight a serious brain cancer in early lab tests. When a company shares new science like this, it's worth watching to see if it actually works in real patients next.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.